Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI115859

Human immunodeficiency virus-infected adherent cell-derived inhibitory factor (p29) inhibits normal T cell proliferation through decreased expression of high affinity interleukin-2 receptors and production of interleukin-2.

A Ammar, Y Sahraoui, A Tsapis, A M Bertoli, C Jasmin, and V Georgoulias

Institut National de la Santé et de la Recherche Médicale (INSERM) U268, Hôpital Paul Brousse, Villejuif, France.

Find articles by Ammar, A. in: JCI | PubMed | Google Scholar

Institut National de la Santé et de la Recherche Médicale (INSERM) U268, Hôpital Paul Brousse, Villejuif, France.

Find articles by Sahraoui, Y. in: JCI | PubMed | Google Scholar

Institut National de la Santé et de la Recherche Médicale (INSERM) U268, Hôpital Paul Brousse, Villejuif, France.

Find articles by Tsapis, A. in: JCI | PubMed | Google Scholar

Institut National de la Santé et de la Recherche Médicale (INSERM) U268, Hôpital Paul Brousse, Villejuif, France.

Find articles by Bertoli, A. in: JCI | PubMed | Google Scholar

Institut National de la Santé et de la Recherche Médicale (INSERM) U268, Hôpital Paul Brousse, Villejuif, France.

Find articles by Jasmin, C. in: JCI | PubMed | Google Scholar

Institut National de la Santé et de la Recherche Médicale (INSERM) U268, Hôpital Paul Brousse, Villejuif, France.

Find articles by Georgoulias, V. in: JCI | PubMed | Google Scholar

Published July 1, 1992 - More info

Published in Volume 90, Issue 1 on July 1, 1992
J Clin Invest. 1992;90(1):8–14. https://doi.org/10.1172/JCI115859.
© 1992 The American Society for Clinical Investigation
Published July 1, 1992 - Version history
View PDF
Abstract

Adherent cells from HIV-infected subjects as well as in vitro HIV-infected normal adherent cells produce spontaneously a 29-kD (p29) factor that inhibits mitogen-induced proliferation of normal T cells. p29 mediates a partial dose-dependent inhibition of total protein synthesis in both nonstimulated and PHA-activated cells that is associated with impaired PHA-induced expression of IL-2 receptor (IL-2R)alpha chain, HLA-class II molecules, and production of IL-2 by these cells; conversely, p29 does not modify the expression of IL-2R beta chain, 4F2, CD9, or transferrin receptor, or the production of IL-1 and TNF alpha by the cells. 1 h preincubation of the cells with p29 is sufficient to detect its biologic activity and added rIL-2 abrogates p29-induced inhibition of IL-2R alpha chain expression; however, p29 does not display any biologic effect on already expressed IL-2R alpha chains. The impaired expression of IL-2R alpha chain mediated by p29 is not due to a decreased accumulation of the corresponding mRNA transcripts, but is associated with a two-fold increase of intracellular cAMP. Binding experiments with 125I-rIL-2 reveals that p29 induces a 50% decrease in the number of both high and low affinity IL-2R per cell. p29 also inhibits alloantigen-induced proliferation of PBMC, whereas it does not modify IL-2-dependent proliferation of 48-h PHA-blasts that already express high affinity IL-2R. These findings indicate that p29 mediates its biologic activity during early stages of T cell activation affecting the expression of high affinity IL-2R and production of IL-2, through a nontranscriptional mechanism involving an increase of intracellular cAMP.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 8
page 8
icon of scanned page 9
page 9
icon of scanned page 10
page 10
icon of scanned page 11
page 11
icon of scanned page 12
page 12
icon of scanned page 13
page 13
icon of scanned page 14
page 14
Version history
  • Version 1 (July 1, 1992): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts